Danaher Co. (NYSE:DHR) Shares Purchased by Manchester Capital Management LLC

Manchester Capital Management LLC increased its holdings in shares of Danaher Co. (NYSE:DHR) by 2.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,515 shares of the conglomerate’s stock after purchasing an additional 113 shares during the period. Manchester Capital Management LLC’s holdings in Danaher were worth $1,037,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of DHR. AMF Tjanstepension AB purchased a new position in shares of Danaher in the 3rd quarter valued at about $5,923,000. Wedge Capital Management L L P NC increased its holdings in Danaher by 3.2% during the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after acquiring an additional 38 shares in the last quarter. Creative Planning increased its holdings in Danaher by 3.1% during the 3rd quarter. Creative Planning now owns 126,340 shares of the conglomerate’s stock valued at $35,125,000 after acquiring an additional 3,749 shares in the last quarter. Probity Advisors Inc. purchased a new position in Danaher during the 3rd quarter valued at about $221,000. Finally, Good Life Advisors LLC acquired a new stake in shares of Danaher during the 3rd quarter worth about $217,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

DHR stock opened at $206.66 on Friday. The company has a market capitalization of $149.26 billion, a P/E ratio of 39.14, a PEG ratio of 2.68 and a beta of 0.83. The company has a 50-day simple moving average of $230.00 and a 200 day simple moving average of $249.96. Danaher Co. has a fifty-two week low of $196.80 and a fifty-two week high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the prior year, the company earned $2.09 earnings per share. Sell-side analysts predict that Danaher Co. will post 7.67 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.52%. The ex-dividend date was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.45%.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 11.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

DHR has been the topic of several research analyst reports. Stifel Nicolaus raised their target price on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Robert W. Baird cut their price target on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. KeyCorp raised their price target on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Scotiabank initiated coverage on shares of Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective on the stock. Finally, Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a research note on Friday, December 13th. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.